New chairman to prepare Leo Pharma for IPO with new launches and financial discipline

Leo Pharma's incoming chairman Jesper Brandgaard says that the company might get listed at some point in the future. Firstly, however, new products must be launched, and the company's earning capacity needs to be improved, according to the former CFO, who operates with a 3-5 year time frame.

Photo: Leo Pharma.

2021 has been a busy year for Leo Pharma.

In March, the company announced that Nordic Capital had secured minority ownership of the company with a DKK 3.4bn (USD 540.9m) investment. Since then, both the pharmaceutical company and the owner fund, the Leo Foundation, have changed their chairmen. On Thursday, Leo Pharma's new chair was announced.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs